← Leaderboards
Liang Qiao
Loyola University Chicago
$4,617,387
Attributed
$5,637,021
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,637,021 · 10
By mechanism
R01$3,651,572 · 4
R21$1,405,624 · 4
R56$502,325 · 1
R03$77,500 · 1
Top collaborators
- Lanying Du2 shared
- Katherine L Knight1 shared
Most similar at Loyola University Chicago
Same institution · by research overlap
- Edward M Campbell$11,979,108
- Katherine L Knight$21,243,692
Others in their field
Top investigators on “Vaccine Development”
- Lawrence Corey · Fred Hutchinson Cancer Center$718,120,301
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$554,939,981
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$394,383,754
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$392,263,550
- Dennis R. Burton · Scripps Research Institute$312,611,400
Research focus
Vaccine DevelopmentPapillomavirusPreventParticleVaccinesImmunizationAntibodiesPlasmidsImmunityImmunogenicVectorGenesNeutralizing AntibodyGenerationsBovine PapillomavirusMucous MembraneVirusLifeImmune ResponseVector VaccineMucosal VaccineMucosal ImmunityPlasmid DnaCytotoxic T-Lymphocytes
Grant awards (17)
A Novel T cell-based Vaccine to Prevent Dengue/Zika virus infection$781,718
R01 · FY2025 · AI · contact PI
Rational design of a unique vaccine for emerging pandemic coronaviruses$755,225
R01 · FY2025 · AI · contact PI
Development of a novel mucosal CTL-based HIV vaccine.$423,500
R21 · FY2025 · AI · contact PI
Development of a mucosal vaccine to prevent Clostridium difficile infection using papilloma pseudovirus as a vector.$502,325
R56 · FY2020 · AI · contact PI
Development of a Flavivirus Vaccine to Reduce Antibody-Dependent Enhancement of Infection$184,560
R21 · FY2020 · AI · contact PI
Development of a hepatitis C virus vaccine using papillomavirus-like particles for antigen delivery$221,844
R21 · FY2019 · AI · contact PI
Development of a Flavivirus Vaccine to Reduce Antibody-Dependent Enhancement of Infection$221,745
R21 · FY2019 · AI · contact PI
Development of a hepatitis C virus vaccine using papillomavirus-like particles for antigen delivery$182,975
R21 · FY2018 · AI · contact PI
Develop an Oral HIV Vaccine Using Papilloma Virus-Like Particles as a Vector$342,038
R01 · FY2012 · DE · contact PI
Develop an Oral HIV Vaccine Using Papilloma Virus-Like Particles as a Vector$335,129
R01 · FY2011 · DE · contact PI
Develop an Oral HIV Vaccine Using Papilloma Virus-Like Particles as a Vector$345,493
R01 · FY2010 · DE · contact PI
Develop an Oral HIV Vaccine Using Papilloma Virus-Like Particles as a Vector$348,983
R01 · FY2009 · DE · contact PI
Develop an Oral HIV Vaccine Using Papilloma Virus-Like Particles as a Vector$372,384
R01 · FY2008 · DE · contact PI
DEVELOPMENT OF A MUCOSAL VACCINE TO TREAT CEA+ TUMORS$188,039
R01 · FY2001 · CA
DEVELOPMENT OF A MUCOSAL VACCINE TO TREAT CEA+ TUMORS$182,563
R01 · FY2000 · CA
INDUCE HIV SPECIFIC MUCOSAL CTL BY PV PSEUDOVIRIONS$171,000
R21 · FY2000 · AI
HIV/HPV CHIMERIC VIRUS PARTICLES AS A MUCOSAL VACCINE$77,500
R03 · FY2000 · AI